title: A phase II study of vascular endothelial growth factor trap (Aflibercept, NSC 724770) in patients with myelodysplastic syndrome: a California Cancer Consortium Study.
authors.affiliation: Department of Hematology/HCT, City of Hope National Medical Center, Duarte, CA, USA.
authors.forename: Mark H
authors.initials: MH
authors.lastname: Kirschbaum
authors.affiliation: Division of Biostatistics, City of Hope National Medical Center, Duarte, CA, USA.
authors.forename: Paul
authors.initials: P
authors.lastname: Frankel
authors.affiliation: Department of Cancer Biology, Beckman Research Institute of City of Hope, Duarte, CA, USA.
authors.forename: Timothy W
authors.initials: TW
authors.lastname: Synold
authors.affiliation: Department of Hematology/HCT, City of Hope National Medical Center, Duarte, CA, USA.
authors.forename: Jasmine
authors.initials: J
authors.lastname: Zain
authors.affiliation: Department of Medicine, Penn State Milton S. Hershey Medical Center, Hershey, PA, USA.
authors.forename: David
authors.initials: D
authors.lastname: Claxton
authors.affiliation: Department of Internal Medicine, UC Davis Comprehensive Cancer Center, Davis, CA, USA.
authors.forename: Joseph
authors.initials: J
authors.lastname: Tuscano
authors.affiliation: Department of Cancer Biology, Beckman Research Institute of City of Hope, Duarte, CA, USA.
authors.forename: Edward M
authors.initials: EM
authors.lastname: Newman
authors.affiliation: Department of Internal Medicine, UC Davis Comprehensive Cancer Center, Davis, CA, USA.
authors.forename: David R
authors.initials: DR
authors.lastname: Gandara
authors.affiliation: Department of Internal Medicine, UC Davis Comprehensive Cancer Center, Davis, CA, USA.
authors.forename: Primo N
authors.initials: PN
authors.lastname: Lara
mesh_terms: D002140:California; D006801:Humans; D009190:Myelodysplastic Syndromes / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D040262:Receptors, Vascular Endothelial Growth Factor / Q000008:administration & dosage / Q000627:therapeutic use*; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D011993:Recombinant Fusion Proteins; C533178:aflibercept; D040262:Receptors, Vascular Endothelial Growth Factor
keywords: clinical trials; myelodysplastic syndrome; vascular endothelial growth factor